DHG Pharmaceutical JSC (STC:DHG) Cyclically Adjusted Revenue per Share: ₫39,047.77 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:DHG DHG Pharmaceutical JSC STC:DHG
78 GF Score
Price ₫93,000.00
GF Value ₫113,826.27
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is DHG Pharmaceutical JSC Cyclically Adjusted Revenue per Share?

DHG Pharmaceutical JSC STC:DHG 78 Cyclically Adjusted Revenue per Share is ₫39,047.77 as of Mar. 2026. GuruFocus rates STC:DHG with a GF Score™ of 78/100 and a GF Value™ of ₫113,826.27 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

DHG Pharmaceutical JSC's adjusted revenue per share for the three months ended in Mar. 2026 was ₫9,163.570. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₫39,047.77 for the trailing ten years ended in Mar. 2026.

During the past 12 months, DHG Pharmaceutical JSC's average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of DHG Pharmaceutical JSC was 6.10% per year. The lowest was 2.70% per year. And the median was 4.40% per year.

As of today (2026-07-15), DHG Pharmaceutical JSC's current stock price is ₫93000.00. DHG Pharmaceutical JSC's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₫39,047.77. DHG Pharmaceutical JSC's Cyclically Adjusted PS Ratio of today is 2.38.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DHG Pharmaceutical JSC was 3.89. The lowest was 2.29. And the median was 2.83.


DHG Pharmaceutical JSC  (STC:DHG) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

DHG Pharmaceutical JSC's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=93000.00/39047.77
=2.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of DHG Pharmaceutical JSC was 3.89. The lowest was 2.29. And the median was 2.83.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


DHG Pharmaceutical JSC Cyclically Adjusted Revenue per Share Related Terms


DHG Pharmaceutical JSC Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for DHG Pharmaceutical JSC's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DHG Pharmaceutical JSC Cyclically Adjusted Revenue per Share Chart

DHG Pharmaceutical JSC Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32,590.99 35,346.03 36,631.62 37,107.89 38,271.06

DHG Pharmaceutical JSC Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37,821.47 38,199.00 38,276.86 38,271.06 39,047.77

STC:DHG vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DHG Pharmaceutical JSC Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DHG Pharmaceutical JSC's Cyclically Adjusted PS Ratio falls into.


STC:DHG
78GF Score
DHG Pharmaceutical JSC STC:DHG
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DHG Pharmaceutical JSC Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DHG Pharmaceutical JSC's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=9163.57/330.2130*330.2130
=9,163.570

Current CPI (Mar. 2026) = 330.2130.

DHG Pharmaceutical JSC Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 6,709.287 241.018 9,192.234
201609 7,023.059 241.428 9,605.785
201612 8,987.610 241.432 12,292.594
201703 10,123.072 243.801 13,711.059
201706 7,080.120 244.955 9,544.397
201709 6,899.043 246.819 9,230.058
201712 10,345.758 246.524 13,857.895
201803 6,948.044 249.554 9,193.739
201806 6,346.492 251.989 8,316.610
201809 5,630.815 252.439 7,365.614
201812 8,288.346 251.233 10,893.949
201903 5,864.717 254.202 7,618.374
201906 7,579.852 256.143 9,771.751
201909 6,405.122 256.759 8,237.509
201912 9,418.797 256.974 12,103.206
202003 6,565.833 258.115 8,399.835
202006 6,033.511 257.797 7,728.343
202009 6,360.377 260.280 8,069.307
202012 8,924.917 260.474 11,314.464
202103 7,781.376 264.877 9,700.772
202106 6,976.770 271.696 8,479.404
202109 6,952.868 274.310 8,369.828
202112 8,363.501 278.802 9,905.728
202203 8,143.847 287.504 9,353.623
202206 8,283.442 296.311 9,231.180
202209 8,602.399 296.808 9,570.578
202212 10,174.602 296.797 11,320.148
202303 9,396.525 301.836 10,279.936
202306 8,535.366 305.109 9,237.646
202309 8,129.648 307.789 8,721.934
202312 11,362.108 306.746 12,231.344
202403 9,625.675 312.332 10,176.745
202406 8,180.926 314.175 8,598.546
202409 7,854.127 315.301 8,225.584
202412 10,796.867 315.605 11,296.608
202503 9,136.377 319.799 9,433.896
202506 8,768.229 322.561 8,976.235
202509 8,481.708 324.800 8,623.061
202512 12,889.630 324.054 13,134.611
202603 9,163.570 330.213 9,163.570

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₫39,047.77 mean?
DHG Pharmaceutical JSC (STC:DHG) has a Cyclically Adjusted Revenue per Share of ₫39,047.77 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DHG Pharmaceutical JSC and its competitors.
Is DHG Pharmaceutical JSC's Cyclically Adjusted Revenue per Share too high?
DHG Pharmaceutical JSC's current Cyclically Adjusted Revenue per Share is ₫39,047.77. Overall, DHG Pharmaceutical JSC has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
DHG Pharmaceutical JSC's Cyclically Adjusted Revenue per Share of ₫39,047.77 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on DHG Pharmaceutical JSC and its competitors. DHG Pharmaceutical JSC's current Cyclically Adjusted Revenue per Share is ₫39,047.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,826.27, compared to a current price of ₫93,000.00 — trading 18.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₫39,047.77. DHG Pharmaceutical JSC's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current Cyclically Adjusted Revenue per Share is ₫39,047.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?

Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued. The current stock price of ₫93,000.00 is trading 18.3% below its estimated GF Value™ of ₫113,826.27. GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.

Key valuation signals for STC:DHG:

  • Cyclically Adjusted Revenue per Share: ₫39,047.77
  • GF Value™: ₫113,826.27 vs. price of ₫93,000.00 (18.3% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DHG Pharmaceutical JSC Business Description

Address 288 Bis Nguyen Van Cu, An Hoa Ward, Ninh Kieu District, Can Tho, VNM
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
78GF Score

Get the complete analysis for STC:DHG

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫93,000.00
Price
₫113,826.27
GF Value